Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Pharm Res. 2013 Jul 27;30(9):2279–2289. doi: 10.1007/s11095-013-1139-8

HCT116 Bax (−) cells were treated with MG132 (1 µM) for 16 hours, and cells were fixed with 4% PFA before immunostaining for Calnexin (green) and Lamp1 (red). Representative fluorescence images are presented in (A). (B) HCT116 Bax (−) cells were treated with MG132 (1 |µM) in the absence or presence of BAPTA-AM (10 µM) for 16 hours followed by Electron Microscopy. Panel a: untreated-control; panels b-c: MG132; panel d: MG132+BAPTA-AM. Panel b’ is an enlarged photograph from the boxed area in panel b. N: nuclei, arrows: dilated ER. Bar: 500 nm.

HCT116 Bax (−) cells were treated with MG132 (1 µM) for 16 hours, and cells were fixed with 4% PFA before immunostaining for Calnexin (green) and Lamp1 (red). Representative fluorescence images are presented in (A). (B) HCT116 Bax (−) cells were treated with MG132 (1 |µM) in the absence or presence of BAPTA-AM (10 µM) for 16 hours followed by Electron Microscopy. Panel a: untreated-control; panels b-c: MG132; panel d: MG132+BAPTA-AM. Panel b’ is an enlarged photograph from the boxed area in panel b. N: nuclei, arrows: dilated ER. Bar: 500 nm.